Pattie S. Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pattie S. Green has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Jay W. Heinecke
From the Department of Medicine, University of Washington, Seattle. Dr Pennathur is currently at the Department of Medicine, University of Michigan, Ann Arbor
2 shared publicationsAndrew B. Moore
From the Department of Medicine, University of Washington, Seattle. Dr Pennathur is currently at the Department of Medicine, University of Michigan, Ann Arbor
1 shared publicationArmando J. Mendez
Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
1 shared publicationBradley T. Hyman
Department of Neurology, Massachusetts General Hospital, Charlestown, Massachussetts, USA
1 shared publicationGuojun Bu
Department of Pediatrics (P.S.G., G.B.), Washington University School of Medicine, St. Louis, Missouri 63110
1 shared publicationJ. Jacob Kulstad
From the Department of Medicine, University of Washington, Seattle. Dr Pennathur is currently at the Department of Medicine, University of Michigan, Ann Arbor
1 shared publication
Latest Publications
- 1 June 2009
- Published by Taylor & Francis in The Physician and Sportsmedicine
- Vol. 37 (2) , 160-161
Addition of Extended-Release Niacin to Statin Therapy: Effects on Atherosclerotic Progression
- 1 June 2009
- Published by Taylor & Francis in The Physician and Sportsmedicine
- Vol. 37 (2) , 160-161
Addition of Extended-Release Niacin to Statin Therapy: Effects on Atherosclerotic Progression
- 16 September 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (12) , 1259-1267
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Background— Boosting low high-density lipoprotein (HDL) levels is a current strategy for preventing clinical events that result from cardiovascular disease. We previously showed that HDL 3 of subjects with coronary artery disease is enriched in apolipoprotein E and that the lipoprotein carries a distinct protein cargo. This observation suggests that altered protein composition might affect the antiatherogenic and antiinflammatory properties of HDL. We hypothesized that an intervention that increases HDL levels—combined statin and niacin therapy—might reverse these changes. Methods and Results— HDL 3 isolated from 6 coronary artery disease subjects before and 1 year after combination therapy was analyzed by liquid chromatography–Fourier transform–mass spectrometry. Alterations in protein composition were detected by spectral counting and confirmed with extracted ion chromatograms. We found that combination therapy decreased the abundance of apolipoprotein E in HDL 3 while increasing the abundance of other macrophage proteins implicated in reverse cholesterol transport. Treatment-induced decreases in apolipoprotein E levels of HDL 3 were validated biochemically in a second group of 18 coronary artery disease subjects. Interestingly, the changes in HDL 3 proteome with niacin/statin treatment resulted in a protein composition that more closely resembled that of HDL 3 in healthy control subjects. Conclusions— Combined statin and niacin therapy partially reverses the changes in the protein composition seen in HDL 3 in coronary artery disease subjects. Our observations raise the possibility that quantifying the HDL proteome could provide insights into the therapeutic efficacy of antiatherosclerotic interventions.
- 16 September 2008
- Published by Wolters Kluwer Health in Circulation
- Vol. 118 (12) , 1259-1267
Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome
Background— Boosting low high-density lipoprotein (HDL) levels is a current strategy for preventing clinical events that result from cardiovascular disease. We previously showed that HDL 3 of subjects with coronary artery disease is enriched in apolipoprotein E and that the lipoprotein carries a distinct protein cargo. This observation suggests that altered protein composition might affect the antiatherogenic and antiinflammatory properties of HDL. We hypothesized that an intervention that increases HDL levels—combined statin and niacin therapy—might reverse these changes. Methods and Results— HDL 3 isolated from 6 coronary artery disease subjects before and 1 year after combination therapy was analyzed by liquid chromatography–Fourier transform–mass spectrometry. Alterations in protein composition were detected by spectral counting and confirmed with extracted ion chromatograms. We found that combination therapy decreased the abundance of apolipoprotein E in HDL 3 while increasing the abundance of other macrophage proteins implicated in reverse cholesterol transport. Treatment-induced decreases in apolipoprotein E levels of HDL 3 were validated biochemically in a second group of 18 coronary artery disease subjects. Interestingly, the changes in HDL 3 proteome with niacin/statin treatment resulted in a protein composition that more closely resembled that of HDL 3 in healthy control subjects. Conclusions— Combined statin and niacin therapy partially reverses the changes in the protein composition seen in HDL 3 in coronary artery disease subjects. Our observations raise the possibility that quantifying the HDL proteome could provide insights into the therapeutic efficacy of antiatherosclerotic interventions.
- Open Access
- 1 June 2005
- Published by The Endocrine Society in Endocrinology
- Vol. 146 (6) , 2774-2781
Estrogen Therapy Fails to Alter Amyloid Deposition in the PDAPP Model of Alzheimer’s Disease
Epidemiological studies implicate estrogen deprivation as a risk factor for Alzheimer’s disease and postmenopausal estrogen replacement as protective factor. One potential mechanism involves estrogen attenuation of β-amyloid (Aβ) peptide accumulation. We examined the effect of estrogen on amyloid accumulation in female PDAPP mice, which express human amyloid precursor protein (APP) with the V717F mutation. These animals deposit Aβ 1–42 in the hippocampus and neocortex and develop Alzheimer-like neuropathology. Mice were subjected to ovariectomy, ovariectomy with estrogen replacement, or sham surgery at 3 months of age, and levels of cerebral Aβ 1–40 and 1–42 were determined after 5 months of treatment. Neither estrogen deprivation nor estrogen replacement altered Aβ accumulation in the hippocampus or neocortex. Similarly, immunoreactivity for full-length human APP and secreted APPα was unchanged. Estrogen status of the animals was confirmed using a variety of techniques, including uterine and pituitary weight, vaginal cytology, and plasma estradiol concentrations. There was no correlation between plasma estradiol levels and accumulation of either Aβ 1–40 or Aβ 1–42 in the brain. Our observations indicate that long-term estrogen therapy does not alter amyloid pathology in PDAPP mice, an animal model of Alzheimer’s disease, and question the role of estrogen in Aβ deposition in brain.
- 1 June 2005
- Published by The Endocrine Society in Endocrinology
- Vol. 146 (6) , 2774-2781
Open AccessEstrogen Therapy Fails to Alter Amyloid Deposition in the PDAPP Model of Alzheimer’s Disease
Epidemiological studies implicate estrogen deprivation as a risk factor for Alzheimer’s disease and postmenopausal estrogen replacement as protective factor. One potential mechanism involves estrogen attenuation of β-amyloid (Aβ) peptide accumulation. We examined the effect of estrogen on amyloid accumulation in female PDAPP mice, which express human amyloid precursor protein (APP) with the V717F mutation. These animals deposit Aβ 1–42 in the hippocampus and neocortex and develop Alzheimer-like neuropathology. Mice were subjected to ovariectomy, ovariectomy with estrogen replacement, or sham surgery at 3 months of age, and levels of cerebral Aβ 1–40 and 1–42 were determined after 5 months of treatment. Neither estrogen deprivation nor estrogen replacement altered Aβ accumulation in the hippocampus or neocortex. Similarly, immunoreactivity for full-length human APP and secreted APPα was unchanged. Estrogen status of the animals was confirmed using a variety of techniques, including uterine and pituitary weight, vaginal cytology, and plasma estradiol concentrations. There was no correlation between plasma estradiol levels and accumulation of either Aβ 1–40 or Aβ 1–42 in the brain. Our observations indicate that long-term estrogen therapy does not alter amyloid pathology in PDAPP mice, an animal model of Alzheimer’s disease, and question the role of estrogen in Aβ deposition in brain.
- 2 July 2004
- Published by Wiley in Journal of Neurochemistry
- Vol. 90 (3) , 724-733
Neuronal expression of myeloperoxidase is increased in Alzheimer's disease
Myeloperoxidase, a heme protein expressed by professional phagocytic cells, generates an array of oxidants which are proposed to contribute to tissue damage during inflammation. We now report that enzymatically active myeloperoxidase and its characteristic amino acid oxidation products are present in human brain. Further, expression of myeloperoxidase is increased in brain tissue showing Alzheimer's neuropathology. Consistent with expression in phagocytic cells, myeloperoxidase immunoreactivity was present in some activated microglia in Alzheimer brains. However, the majority of immunoreactive material in brain localized with amyloid plaques and, surprisingly, neurons including granule and pyramidal neurons of the hippocampus. Confirming neuronal localization of the enzyme, several neuronal cell lines as well as primary neuronal cultures expressed myeloperoxidase protein. Myeloperoxidase mRNA was also detected in neuronal cell lines. These results reveal the unexpected presence of myeloperoxidase in neurons. The increase in neuronal myeloperoxidase expression we observed in Alzheimer disease brains raises the possibility that the enzyme contributes to the oxidative stress implicated in the pathogenesis of the neurodegenerative disorder.
- 2 July 2004
- Published by Wiley in Journal of Neurochemistry
- Vol. 90 (3) , 724-733
Neuronal expression of myeloperoxidase is increased in Alzheimer's disease
Myeloperoxidase, a heme protein expressed by professional phagocytic cells, generates an array of oxidants which are proposed to contribute to tissue damage during inflammation. We now report that enzymatically active myeloperoxidase and its characteristic amino acid oxidation products are present in human brain. Further, expression of myeloperoxidase is increased in brain tissue showing Alzheimer's neuropathology. Consistent with expression in phagocytic cells, myeloperoxidase immunoreactivity was present in some activated microglia in Alzheimer brains. However, the majority of immunoreactive material in brain localized with amyloid plaques and, surprisingly, neurons including granule and pyramidal neurons of the hippocampus. Confirming neuronal localization of the enzyme, several neuronal cell lines as well as primary neuronal cultures expressed myeloperoxidase protein. Myeloperoxidase mRNA was also detected in neuronal cell lines. These results reveal the unexpected presence of myeloperoxidase in neurons. The increase in neuronal myeloperoxidase expression we observed in Alzheimer disease brains raises the possibility that the enzyme contributes to the oxidative stress implicated in the pathogenesis of the neurodegenerative disorder.